• Detecting cell-surface antigens on malignant cells that are potential therapeutic antibody targets, specifically CD52
• Determining the eligibility of patients for monoclonal antibody therapies
• Monitoring response to the therapeutic antibody

Yellow ACD (A or B)

Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting

Send specimen in original tube. Do not aliquot.

Yellow ACD (A or B)

Whole blood or Bone Marrow:

Dk green Sodium heparin (Na hep), no gel

Lavender (EDTA), 4mL

Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting

Send specimen in original tube. Do not aliquot.

Dk green Sodium heparin (Na hep), no gel

Lavender (EDTA), 4mL

The following information is required:

1. The therapeutic monoclonal antibody being used or considered
2. The pertinent hematologic diseases that have been diagnosed or considered
3. Specimen source

Ambient (preferred) – 4 days

Refrigerated – 4 days

Immunophenotyping

The immunophenotyping report will summarize the pattern of antigenic expression on malignant cells and, if appropriate, the normal cellular counterparts that correspond to the therapeutic monoclonal antibody target.